Obagi’s Saypha ChIQ Wins FDA Approval for Cheek Augmentation

Final fall, Obagi Medical formally entered the injectable house with the launch of Saypha MagIQ, its FDA-approved hyaluronic acid filler for average to extreme nasolabial folds. The transfer marked a significant evolution for the skin-care large, placing it in direct competitors with established filler portfolios like RHA, Restylane and Juvéderm.

This week, the model expanded that portfolio once more. Obagi introduced FDA approval of Saypha ChIQ, a hyaluronic acid filler designed for cheek augmentation and correction of midface contour deficiencies in sufferers over 21. The brand new approval makes ChIQ the second injectable underneath Obagi’s rising aesthetics umbrella, additional signaling the model’s ambitions to turn out to be a extra complete participant within the class.

Like MagIQ, ChIQ comes out of Obagi’s partnership with Austria-based Croma-Pharma, the worldwide aesthetics firm behind the Saypha filler line. Whereas the model could really feel newer to U.S. injectors, Croma has been within the injectable house for many years, with greater than 130 million syringes distributed throughout 80 international locations.

On the core of ChIQ is Croma’s MACRO Core Know-how, a specialised hyaluronic acid matrix designed for larger elevate and structural assist. The result’s a filler higher fitted to creating form, contour and projection within the cheeks and midface.

“The FDA approval of ChIQ is thrilling as a result of it fills an necessary hole,” says Austin, TX oculoplastic surgeon Sheila Barbarino, MD. “It’s the next G-prime hyaluronic acid filler designed to offer enhanced structural assist and elevate. I’ve had nice success with Obagi’s present HA filler, MagIQ, which has turn out to be a real workhorse in my follow because of its versatility, predictability and natural-looking outcomes. The addition of ChIQ expands the portfolio and provides suppliers and sufferers one other priceless choice for these searching for larger definition, contour and longevity whereas sustaining a refined, pure aesthetic.”

With ChIQ, Obagi continues to broaden past skincare, constructing out an injectable lineup that enhances the remedies many suppliers are already pairing with topical regimens. And in a crowded filler market, it provides injectors another choice backed by many years of world expertise.